Birtamimab is under clinical development by Prothena Corp and currently in Phase III for Primary Systemic Amyloidosis. According to GlobalData, Phase III drugs for Primary Systemic Amyloidosis does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Birtamimab LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Birtamimab overview
Birtamimab (NEO-D001) is under development for the treatment of primary systemic amyloidosis. The drug candidate is administered intravenously as powder for solution. NEOD-001 is a monoclonal antibody that targets aberrant amyloid protein. It was also under development for secondary systemic amyloidosis.
Prothena Corp overview
Prothena Corp (Prothena) discovers and develops therapies for the treatment of neurological disorders. The company’s pipeline products include Prasinezumab, Birtamimab, NNC6019/PRX004, BMS-986446 (PRX005), PRX012, PRX123, PRX019, TDP-43. It is an investigational monoclonal antibody, which treats AL Amyloidosis; Prasinezumab, a monoclonal antibody, which targets alpha-synuclein protein, against Parkinson’s disease; NNC6019 (PRX004) for ATTR amyloidosis; BMS-986446 (PRX005), PRX012 and PRX123 which treats Alzheimer’s disease. Prothena works in collaboration with Roche Holding AG, Bristol Myers Squibb and other companies to develop its products. Prothena is headquartered in Dublin, Ireland.
For a complete picture of Birtamimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
